Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 3, 2013, Pages 203-212

  Takata, Tohru ^a,b   Miyazaki, Motoyasu ^a,c   Futo, Maki ^a,c   Hara, Shuji ^c   Shiotsuka, Shouichi ^b   Kamimura, Hidetoshi ^c   Yoshimura, Hisae ^b   Matsunaga, Akira ^b   Nishida, Takeshi ^b   Ishikura, Hiroyasu ^b   Ishikawa, Takahiko ^a,d   Tamura, Kazuo ^a   Tsuji, Brian T ^e  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

^d UMEÅ UNIVERSITY   (Sweden)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

lactam antibiotic induced vancomycin resistance; Bacteremia; Clinical outcome; Heterogeneous vancomycin intermediate resistance; MRSA

Indexed keywords

BETA LACTAM ANTIBIOTIC; METICILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ADULT; AGAR DILUTION; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; EPSILOMETER TEST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMS; COMORBIDITY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHENOTYPE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE;

EID: 84874027945     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.723221     Document Type: Article

References (37)

1. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to van-comycin. Lancet 1997; 350: 1670-3.
2. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009; 47: 1640-4.
3. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008; 46: 2950-4.
4. Fitzgibbon MM, Rossney AS, O'Connell B. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus. J Clin Microbiol 2008; 45: 3263-9.
5. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38: 448-51.
6. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
7. Ike Y, Arakawa Y, Ma X, Tatewaki K, Nagasawa M, Tomita H, et al. Nationwide survey shows that methicillin-resistant Sta-phylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J Clin Microbiol 2001; 39: 4445-51.
8. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-24.
9. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical sig-nificance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47: 3040-5.
10. Fong RK, Low J, Koh TH, Kurup A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylo-coccus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis 2009; 28: 983-7.
11. Ariza J, Pujol M, Cabo J, Peña C, Fernández N, Liñares J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353: 1587-8.
12. Bae IG, Federspiel JJ, Miró JM, Woods CW, Park L, Rybak MJ, et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical sig-nificance. J Infect Dis 2009; 200: 1355-66.
13. Neoh HM, Hori S, Komatsu M, Oguri T, Takeuchi F, Cui L, et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob 2007; 6: 13.
14. Walsh TR, Bolmström A, Qwärnström A, Ho P, Wootton M, Howe RA, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39: 2439-44.
15. Chen H, Liu Y, Sun W, Chen M, Wang H. The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC. Diagn Microbiol Infect Dis 2011; 71: 301-3.
16. Hanaki H, Yamaguchi Y, Nomura S, Haraga I, Nagayama A, Sunakawa K. Method of detecting beta-lactam antibiotic induced vancomycin resistant MRSA (BIVR). Int J Antimi-crob Agents 2004; 23: 1-5.
17. Hanaki H, Yamaguchi Y, Yanagisawa C, Uehara K, Matsui H, Yamaguchi Y, et al. Investigation of beta-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR). J Infect Chemother 2005; 11: 104-6.
18. Yanagisawa C, Hanaki H, Matsui H, Ikeda S, Nakae T, Sunakawa K. Rapid depletion of free vancomycin in medium in the presence of beta-lactam antibiotics and growth restoration in Staphylococcus aureus strains with beta-lactam-induced vancomycin resistance. Antimicrob Agents Chemother 2009; 53: 63-8.
19. Yamaguchi Y, Hanaki H, Yanagisawa C, Ikeda-Dantsuji Y, Hashimoto T, Yazaki H, et al. Characterization of beta-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) in a patient with septicemia during long-term vancomycin administration. J Infect Chemother 2009; 15: 274-8.
20. Miyazaki M, Takata T, Yoshimura H, Matsunaga A, Ohta D, Ishikura H, et al. Vancomycin bactericidal activity as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2011; 55: 1819-20.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010.
22. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multi-center study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007; 45: 329-32.
23. Knaus W A, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
24. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
25. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bac-teremia caused by Staphylococcus aureus. Arch Intern Med 1998; 158: 182-9.
26. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
27. Kim MN, Hwang SH, Pyo YJ, Mun HM, Pai CH. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J Clin Microbiol 2002; 40: 1376-80.
28. Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999; 29: 760-7.
29. Wong SS, Ng TK, Yam WC, Tsang DN, Woo PC, Fung SK, et al. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 2000; 36: 261-8.
30. Haraga I, Nomura S, Fukamachi S, Ohjimi H, Hanaki H, Hiramatsu K, et al. Emergence of vancomycin resistance during therapy against methicillin-resistant Staphylococcus aureus in a burn patient-importance of low-level resistance to vancomycin. Int J Infect Dis 2002; 6: 302-8.
31. Brunet F, Vedel G, Dreyfus F, Vaxelaire JF, Giraud T, Schremmer B, et al. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J Clin Microbiol Infect Dis 1990; 9: 145-7.
32. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55.
33. van Hal SJ, Paterson DL. Systematic review and meta-anal-ysis of the significance of heterogeneous vancomycin-inter-mediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55: 405-10.
34. Takata T, Miyazaki M, Li H, Healy M, Frye S, Tanaka K, et al. Methicillin-resistant Staphylococcus aureus bloodstream infections in a Japanese University Hospital between 1987 and 2004. J Infect Chemother 2012; 18: 199-206.
35. Hatano K, Yokota Y, Hanaki H, Sunakawa K. Combined effect of vancomycin or teicoplanin plus a beta-lactam antibiotic in mouse infection models caused by beta-lactam antibiotic-induced vancomycin resistant MRSA (BIVR). Kansenshogaku Zasshi 2006; 80: 243-50.
36. Gómez J, García-Vázquez E, Baños R, Canteras M, Ruiz J, Baños V, et al. Predictors of mortality in patients with methi-cillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis 2007; 26: 239-45.
37. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influ-ence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis 2008; 198: 336-43.